Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
about
Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging conceptsVessel caliber--a potential MRI biomarker of tumour response in clinical trials.A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the boneCirculating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Circulating tumor cells as biomarkers in prostate cancer.Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients.Imaging response assessment in oncologyMolecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapyDepartment of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.Developing imaging strategies for castration resistant prostate cancerChallenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice.Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerAssessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.Novel tracers and their development for the imaging of metastatic prostate cancer.Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative StudyCurrent approaches, challenges and future directions for monitoring treatment response in prostate cancer.Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CTSafety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer.End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.Validation and clinical utility of prostate cancer biomarkers.Managing bone metastases and reducing skeletal related events in prostate cancer.Circulating tumour cells-monitoring treatment response in prostate cancer.Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.Prostatic metastases and polycythemia vera on bone magnetic resonance imaging: A case report.A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
P2860
Q26863654-935E6893-22A5-45C4-8DFD-55316ED763D9Q30651792-100E3569-D47A-449D-8AD9-C828ECA26954Q31140219-B4EA03B7-45A7-464F-9FA9-3EF8C4E22A39Q33408667-8D175D5F-3254-41D3-9AF4-F2084564401DQ33408846-06CE60C4-2348-4A2B-B8AA-59687F8BA3DFQ33566395-084A3496-2B0B-4FAA-9D18-0E2CA790BF7EQ34108738-15438BDE-118D-4044-AC83-896DEE124634Q34193303-1679B0B2-180E-4178-A2ED-6459D18E19CFQ34807126-0EA7D0BA-D6BF-4B0A-A23A-E9F2485A30BCQ35148246-49BE072B-DE33-49E3-8B28-7145ADC9CE89Q35650697-C06F3CF0-D545-4EDE-9A8C-550AD640923EQ35793157-0BA00574-87D7-4A59-964D-D10E8AD3E6D7Q36087881-FCAFB942-6055-464C-8843-450F2F3C14FFQ36152211-EF678F63-165D-4035-8E92-78255E39C8DBQ36181578-911B02BF-C64E-44C6-85FA-0874D0C177FFQ36243296-B1562503-C23B-4DB6-8514-A6F3E1B9CB49Q36353287-50068E7A-5EDC-406B-B71D-F076E8973A70Q36429530-67E346C1-22F1-4FF2-ACA7-9A32D8C97A4AQ36478792-D8A52FD1-312E-4713-9DB7-0BD327D9339BQ36677570-A9C67064-67C1-4619-9948-7C9BF14339AFQ36931715-8FE94D2A-0E7D-43CF-953A-8EB01BED6127Q37255452-4A3DF51B-D0FE-42F1-9087-0A2823ED9C61Q37321810-8769C308-F279-41C4-8A17-48BEBA855493Q37426036-0932DA59-CC93-4FF4-B810-8E3644D74609Q37435181-8D4DE927-2DCD-49D2-AAD0-512557FB686CQ37496697-06EC2E57-7F02-444A-8398-7AAACE595722Q37658520-8C2A934A-FE2C-4F92-BE95-F40E629DDCA5Q37921009-2320EB99-8DC7-4A9F-933F-A3990A31847FQ38029394-482371D9-3534-40B0-9792-41BEBDBF3678Q38086420-C4AD410B-A94E-4A60-ABD3-A7893EA3D83CQ38211359-679E2E2F-BEAE-4359-8904-580FEC5E2E65Q38211361-E145751A-4533-4698-9264-A8702FE15465Q38333802-82ECBCE4-4D72-40E1-9BBA-6CB940969A0FQ38407976-5B6C31AD-2FBF-4C8A-AEC3-3424281745BAQ38766102-9DF8C545-CA4C-4CD1-AB2D-206D56A64A1BQ38777057-B3D0DF47-5D45-4B8E-BE56-F2A3020E74E0Q39041834-E471BC9F-7EE8-4437-AA0E-F4269B032D20Q40745246-FB33F5CA-ACE8-464D-99AC-DDAE89B46A86Q41466174-22678067-D840-42DE-937E-12902492E453Q41831050-B67B20CD-19F7-478E-B5A0-3FA9CCA0E45A
P2860
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@ast
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@en
type
label
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@ast
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@en
prefLabel
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@ast
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
@en
P2093
P2860
P1476
Prostate cancer clinical trial end points: "RECIST"ing a step backwards
@en
P2093
Glenn Heller
Howard I Scher
Lawrence H Schwartz
William K Kelly
P2860
P304
P356
10.1158/1078-0432.CCR-05-0109
P407
P577
2005-07-01T00:00:00Z